1001756-21-3

Basic information

• Product Name: 4-amino-6-chloronicotinaldehyde
• Synonyms: 4-amino-6-chloronicotinaldehyde
• CAS NO: 1001756-21-3
• Molecular Formula: C₆H₅ClN₂O
• Molecular Weight: 156.5697
• Mol File: 1001756-21-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 379.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.442±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.58±0.42(Predicted)
• CAS DataBase Reference: 4-amino-6-chloronicotinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-6-chloronicotinaldehyde(1001756-21-3)
• EPA Substance Registry System: 4-amino-6-chloronicotinaldehyde(1001756-21-3)

Safety Data

• Hazardous Substances Data: 1001756-21-3(Hazardous Substances Data)

Usage

General Description

4-amino-6-chloronicotinaldehyde is a chemical compound with the molecular formula C6H5ClN2O. It is a derivative of nicotinaldehyde, and its structure consists of a pyridine ring with an amino group at the 4 position and a chlorine atom at the 6 position. 4-amino-6-chloronicotinaldehyde is used in organic synthesis and pharmaceutical research. It has been studied for its potential medicinal properties, particularly as an anti-tuberculosis agent. Additionally, it has been investigated for its potential use in the development of fluorescent probes for biological imaging. 4-amino-6-chloronicotinaldehyde has also been found to have antibacterial and antifungal properties, making it a valuable compound in various scientific and industrial applications.

InChI:InChI=1S/C6H5ClN2O/c7-6-1-5(8)4(3-10)2-9-6/h1-3H,(H2,8,9)

Upstream product

• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1588423-42-0 ethyl 6-chloro-4-((2,4-dimethoxybenzyl)amino)nicotinate 
• 380626-81-3 ethyl 4-amino-6-chloropyridine-3-carboxylate 
• 1391740-89-8 ethyl 6-chloro-4-[(4-methoxyphenyl)methylamino]pyridine-3-carboxylate 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 1256785-40-6 methyl 4-amino-6-chloro-pyridine-3-carboxylate 
• 1374215-05-0 methyl 4-(benzylamino)-6-chloronicotinate 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 846036-96-2 (4-amino-6-chloropyridin-3-yl)methanol 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 

Downstream Products

• 1386447-86-4 3-({7-[(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-amino]-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl}-amino)-benzoic acid methyl ester 
• 1455035-79-6 5-(7-chloro-2-methyl-1,6-naphthyridin-3-yl)-2-fluoroaniline 
• 1588422-41-6 C₃₁H₃₁N₅O₂ 
• 1588422-66-5 3-(2,6-difluorophenyl)-7-((5-fluoropyridin-2-yl)amino)-1-phenyl-1,6-naphthyridin-2(1H)-one 
• 1588423-44-2 7-chloro-1-methyl-3-phenyl-1,6-naphthyridin-2-(1H)-one 
• 1588423-58-8 C₂₀H₁₁ClF₂N₂O 
• 1588423-92-0 C₂₀H₁₃ClN₂O 
• 1588423-93-1 C₁₇H₁₅ClN₂O 
• 1588421-99-1 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-00-7 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-1-methyl-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-03-0 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-isopropyl-1-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588423-43-1 C₁₄H₉ClN₂O 
• 1588423-57-7 C₁₄H₇ClF₂N₂O 

Relevant articles and documents

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d ]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficac

RAF INHIBITOR COMPOUNDS

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.